| 翻訳と辞書 |
| lorvotuzumab mertansine ： ウィキペディア英語版 |
lorvotuzumab mertansine
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).〔(ImmunoGen reports encouraging clinical data of IMGN901 ). News-medical.net. Retrieved on 2010-11-20.〕
It has been granted Orphan drug status for Merkel cell carcinoma.〔http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx〕
It has reported encouraging Phase II results for small-cell lung cancer.〔(【引用サイトリンク】title=ImmunoGen Announces Encouraging New Clinical Data With The Company’s IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer )〕
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「lorvotuzumab mertansine」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|